While Janssen admitted no wrongdoing, this deal is separate from another Risperdal settlement that could cost the company as much as $2 billion or more. For Genmab, the news of their deal can only be good for that company's balance sheet. This report (PDF) shows 5.4 million shares of company stock being acquired by the American company. The company headed by Prof. Jan G. J. van de Winkel, Ph.D. (at right) was founded in Copenhagen, Denmark in 1999. A publicly traded Danish company, Genmab employs 180 plus people at their headquarters and clinical development facilities, as well as at their admin office in Holland and in the US.
The company specializes in the creation and development of very special and differentiated human antibody therapeutics aimed at treating cancer. Their contemporaries, and in this news beneficiaries, Jannsen Biotech, leads in many areas of treatment including; immunology, oncology and nephrology, among others.
Johnson & Johnson is one of the most respected brands in the world. Whether big court cases supersede the company's positive moves toward helping defeat cancer offset, it is clear that J & J and other big corporations exert a great deal of resource in defending themselves in the courts. For many the monies laid out to cover these costs could be so much better applied to the science of healing. Still, some litigation always seems inevitable too, the "up and down" of doing business. Too bad.
PR agencies who have worked with various Johnson & Johnson divisions include Ruder Finn, Edelman PR and Hunter PR in New York.
While Janssen admitted no wrongdoing, this deal is separate from another Risperdal settlement that could cost the company as much as $2 billion or more. For Genmab, the news of their deal can only be good for that company's balance sheet. This report (PDF) shows 5.4 million shares of company stock being acquired by the American company. The company headed by Prof. Jan G. J. van de Winkel, Ph.D. (at right) was founded in Copenhagen, Denmark in 1999. A publicly traded Danish company, Genmab employs 180 plus people at their headquarters and clinical development facilities, as well as at their admin office in Holland and in the US.
The company specializes in the creation and development of very special and differentiated human antibody therapeutics aimed at treating cancer. Their contemporaries, and in this news beneficiaries, Jannsen Biotech, leads in many areas of treatment including; immunology, oncology and nephrology, among others.
Johnson & Johnson is one of the most respected brands in the world. Whether big court cases supersede the company's positive moves toward helping defeat cancer offset, it is clear that J & J and other big corporations exert a great deal of resource in defending themselves in the courts. For many the monies laid out to cover these costs could be so much better applied to the science of healing. Still, some litigation always seems inevitable too, the "up and down" of doing business. Too bad.
PR agencies who have worked with various Johnson & Johnson divisions include Ruder Finn, Edelman PR and Hunter PR in New York.
Written by
Editorial Team
The Everything-PR Editorial Team produces reporting, research, and analysis across thirty verticals — communications, reputation, AI visibility, public affairs, media systems, and digital discovery in the answer-engine era. Publishing since 2009.
Other news
See all
Editorial Team · 05/23/2026
Beauty PR in 2026: Influencer Fatigue, AI Search, and the Return of Earned Media
The beauty category was an early case study in influencer-driven brand building. The structural shifts now reshaping the category — influencer fatigue, AI-driven product discovery, retail consolidation, and shifting consumer trust — make the current period more interesting and mo
Editorial Team · 05/23/2026
Prompt-Shaped Content: Writing Nonprofit Pages That LLMs Retrieve and Cite
Answer engines retrieve content built to match the shape of a question. Most nonprofit content is built for appeals and keywords.
Editorial Team · 05/23/2026
The AI Communications Stack
Seven layers. Skip one and the engine skips you. Most AI visibility problems are not media problems. They are stack problems. One layer is broken — and the engine skips the entity entirely.
Never Miss a Headline
Daily PR headlines, weekly long-form analysis, and our proprietary research drops — straight to your inbox.